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TheScientificWorldJOURNAL (2003) 3 , 1327-1331 FIGURE 1. Increased expression of ICAM-1 in syndecan-1 knockout mice relative to wild-type mice subjected to delayed-type hypersensitivity (DTH). A DTH response to oxazolone was elicited in syndecan-1 wild-type (Sdc1+/+) and knockout (Sdc1-/-) mice [11] . Oxazolone-treated ears were harvested at the peak of the inflammatory response and cryosectioned. After immunostaining with ICAM-1 (left and central panel) or rat IgG isotype control (right panel) primary antibodies, and AlexaFluor488 conjugated goat-antirat secondary antibodies (green staining), the sections were subjected to confocal laser microscopy as described [12] . Nuclei were stained with propidium iodide (red staining). regulation of inflammation [4] . For example, mice lacking syndecan-1 display increased leukocyteendothelial interactions and angiogenesis, as well as increased inflammatory responses in experimentally induced delayed-type hypersensitivity [10, 11] (Fig. 1) . The major functional domains of the syndecans, their heparan sulfate chains, have been implicated in regulating the activity of chemokines for some time [13, 14, 15] : All chemokines bind to HS through positively charged domains, and for many chemokines a modulation of their activity by HS has been demonstrated (reviewed in [4] ). For example, HS binding to IL-8 leads to a structural stabilization of the dimeric form of the chemokine, which results in a prolonged biological activity and enhanced neutrophil responses to IL-8 [13, 16, 17, 18] . Most recently, it has been demonstrated that glycosaminoglycan binding and the capability to oligomerize are essential requirements for the activity of a number of chemokines in vivo [19] .
The study published by Li et al. [5] confirms and extends these findings on the role of HSPGs, and establishes a role for syndecan-1 in the formation of chemokine gradients. Following their initial observation of an increased expression of the matrix-metalloprotease matrilysin (MMP-7) in lungs injured by bleomycin instillation, they subjected matrilysin knockout (MAT-/-) mice to bleomycin-induced lung fibrosis. MAT-/-mice were found to be protected against bleomycin-induced lethality to a surprisingly high extent: At a bleomycin dose that led to lethality in all control mice after 10 days, 80% of the MAT-/-mice were still alive. Apart from the survival benefit, a reduction in alveolar fibrosis was noted in the knockout mice. An impaired ability of neutrophils to migrate from the interstitium into the lumenal compartment was identified as the cause of the reduced mortality of MAT-/-mice. This could clearly be demonstrated by instilling the chemotactic peptide nFNLP along with bleomycin: The forced neutrophil influx restored bleomycin-induced lethality in the MAT-/-mice. The authors were able to unravel the molecular mechanism underlying the neutrophil compartmentalization in the MAT-/-mice when they discovered that the CXC chemokine KC, a functional homologue of human IL-8, was markedly elevated in the bronchoalveolar lavage of bleomycintreated wild-type mice, but remained at baseline levels in MAT-/-mice. Interestingly, KC protein levels were elevated in total lung extracts, but remained constant in wild-type lung extracts following bleomycin treatment. Thus, KC was present, but could not be released into the alveolar space. In an elegant set of experiments, Li et al. could finally demonstrate that KC can be coimmunoprecipitated with the ectodomain of syndecan-1, and that matrilysin induces the shedding of syndecan-1 from the surface of the lung epithelium. Syndecan-1-/-revealed similar results as FIGURE 2. Generation of a chemokine gradient by syndecan-1 in a model of pulmonary fibrosis (cf. [5] ). Left panel: the chemokine KC (green) is bound to syndecan-1 (blue) and shed from the lung epithelium into the alveolar space (AS) on cleavage of the syndecan-1 core protein by matrilysin (red). In bleomycin-treated wild-type, neutrophils extravasate from alveolar capillaries (AC) and follow the KC/syndecan-1 gradient, leading to a massive influx of neutrophils into the alveolar space and ultimately to lung fibrosis. Right panel: in matrilysin-deficient mice, the complex of KC and syndecan-1 remains at the epithelial cell surface. Neutrophils are only found at the epithelium, but not in the alveolar space, resulting in decreased lung fibrosis and mortality FIGURE 3. Generation of a transendothelial interleukin-8 gradient by syndecan-1 (cf. [6] ). Left panel: interleukin-8 (green) is bound to syndecan-1 (blue), which forms a gradient at the surface of HUVEC cells. Neutrophils are directed to this chemotactic gradient, resulting in a recruitment to the HUVEC surface and ultimately in transmigration. In the presence of plasminogen activator inhibitor-1 (PAI), plasminogen activators (PA) are kept inactive, and plasminogen (orange) is not activated. Right panel: on inactivation or down-regulation of PAI-1, plasminogen activators generate plasmin (red), which is shedding syndecan-1/IL-8 complexes from the HUVEC surface. The chemotactic gradient for neutrophils is destroyed, resulting in decreased transmigration of neutrophils.
MAT-/-mice in terms of KC levels in lung tissue and bronchoalveolar lavage and a reduction in neutrophil numbers after bleomycin treatment. In summary, the data indicate that matrilysin generates a transepithelial chemotactic gradient by releasing a complex of syndecan-1 and the chemokine KC into the alveolar space (Fig. 2) .
A role for syndecan-1 in the generation of a chemokine gradient was also demonstrated by Marshall et al. [6] , who observed that the major part of IL-8 was present in the culture media of HUVEC cells, but not cell associated. The authors could show an increased cell association of IL-8 in the presence of the protease inhibitor aprotinin, or PAI-1, respectively. Inhibition of PAI-1 activity with a blocking antibody resulted in increased shedding of syndecan-1, which could be coimmunoprecipitated with IL-8, into the HUVEC culture medium. Interestingly, PAI-1 inhibition did not only increase the release of syndecan-1/IL-8 complexes, it also reduced transendothelial migration of neutrophils in a dose-dependent manner. This effect could be reverted by the plasmin inhibitor aprotinin. The study suggests that shedding of syndecan-1/IL-8 complexes is mediated by plasmin, and that PAI-1 stabilizes the chemoattractant form of IL-8, complexed to syndecan-1, at the endothelial cell surface (Fig. 3) .
In summary, a role for syndecan-1 in the generation of chemokine gradients was demonstrated both for neutrophils migrating though an epithelium and through an endothelial cell layer. In both cases, proteases mediated the shedding of chemokine-syndecan-1 complexes, which served as a leukocyte chemoattractant.
However, the consequences of protease-mediated shedding were different: In lung epithelium, a soluble gradient was required to support neutrophil migration, whereas in the case of the endothelium, the syndecan-1/chemokine complex was required at the cell surface. It has been shown that soluble IL-8 has inhibitory effects on inflammation (e.g., neutrophil recruitment), whereas a proinflammatory effect has been ascribed to cell-surface bound IL-8 (discussed in [6] ). Thus, neutrophil migration through endothelial cell layers and epithelia appear to have different requirements (cf. [20] ). Both studies bring previous, seemingly unrelated data into a functional context: Binding of chemokines to the HS chains of syndecan-1 is not only a means of stabilizing the chemokine in an active, oligomeric form [15, 18, 19] , it also provides a means of selectively regulating the (trans)migration of neutrophils through protease-mediated shedding of the syndecan ectodomain [5, 6, 9] . These results help to explain the observation of increased leukocyte-endothelial interactions, inflammation, and angiogenesis in a mouse model lacking syndecan-1 [10, 11] . In addition, they open up new pathways for the treatment of diseases like pulmonary fibrosis, chronic inflammation, and cancer through the development of selective syndecan-shedding inhibitors, and the potential use of syndecan-1, or syndecan-1-neutralizing reagents as therapeutics.
